Skip to content

The American Journal of Drug and Alcohol Abuse

ISSN 0095-2990, 1097-9891

33 papers in the library · 1,712 citations · publishing 1975-2025

Papers

Sort Most recent Most cited

Ketamine to enhance methadone treatment retention in patients with opioid use disorder and co-morbid depression

The American Journal of Drug and Alcohol Abuse August 22, 2025 Peter Manza, Annabelle M. Belcher, Heather Fitzsimons et al.

ABSTRACT Background: Opioid use disorder (OUD) is a chronic relapsing condition with a high mortality rate. While medications such as methadone are valuable first-line therapies, retention is poor, with the highest dropout rates early in a treatment attempt. Poor outcomes are due in part to the very high rates of co-morbid depression in people with OUD, as depression can drive opioid use....

Plasma leptin levels are lower in females, but not males, with ketamine use disorder.

The American Journal of Drug and Alcohol Abuse September 2, 2024 Ming-Chyi Huang, Li-Jung Chiang, Wan-Hsi Chien et al.

Background: Ketamine has emerged as a prominent substance of misuse. Leptin, an adipocyte-derived polypeptide hormone, has been implicated in the development of addiction. Sex-specific changes in leptin levels have been demonstrated following acute ketamine administration; the persistence of long-term ketamine use on leptin levels is uncertain.Objectives: To assess the sex-difference of leptin...

DOI: 10.1080/00952990.2024.2394963 (opens in new tab) Full text (opens in new tab) Leptin Early abstinence Females Ketamine use disorder +6

Ancient medicine for a modern disease: traditional Amazonian medicine to treat substance use disorders.

The American Journal of Drug and Alcohol Abuse November 2, 2023 Fernando Mendive, Cecile Giovannetti, Sara García Arce 4 citations

Background: There exists an underexploited opportunity to develop innovative therapeutic approaches to SUDs based upon the complementarity between modern and traditional health systems.Objectives: Illustrate the feasibility and potentiality of such an approach through the comprehensive description of Takiwasi Center's treatment model and program, where health concepts and practices from...

Tusi: a new ketamine concoction complicating the drug landscape.

The American Journal of Drug and Alcohol Abuse September 3, 2023 Joseph J Palamar 29 citations

A drug concoction called tusi has emerged in Latin America and in Europe and is now beginning to acquire popularity in the United States. "Tusi" is a phonetic translation of "2C," a series of psychedelic phenethylamines. The concoction is also sometimes referred to as "pink cocaine" as it typically comes in the form of pink powder. However, despite its name, the concoction rarely contains 2C...

Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico.

The American Journal of Drug and Alcohol Abuse September 3, 2023 Alan Kooi Davis, Yitong Xin, Nathan D. Sepeda et al. 29 citations

Background: Research in psychedelic medicine has focused primarily on civilian populations. Further study is needed to understand whether these treatments are effective for Veteran populations.Objectives: Here, we examine the effectiveness of psychedelic-assisted therapy among trauma-exposed Special Operations Forces Veterans (SOFV) seeking treatment for cognitive and mental health problems in...

Successful treatment of dextromethorphan use disorder with combined naltrexone and gabapentin: a case report

The American Journal of Drug and Alcohol Abuse March 4, 2023 Nicole Ledwos, Aurelia I Andreiev, Tianna Costa et al.

NyQuil is an over-the-counter medication containing the pain reliever, acetaminophen; the antihistamine, doxylamine; and dextromethorphan (DXM), the antitussive medication. The Nyquil liquid formulation also contains alcohol, listed among the inactive ingredients. DXM has dependence-producing properties and addiction liability, especially in young people (1). Large doses (>1500 mg/day) can...

Predicting changes in substance use following psychedelic experiences: natural language processing of psychedelic session narratives

The American Journal of Drug and Alcohol Abuse June 5, 2021 David J. Cox, Albert Garcia‐romeu, Matthew W. Johnson 29 citations

Background: Experiences with psychedelic drugs, such as psilocybin or lysergic acid diethylamide (LSD), are sometimes followed by changes in patterns of tobacco, opioid, and alcohol consumption. But, the specific characteristics of psychedelic experiences that lead to changes in drug consumption are unknown.Objective: Determine whether quantitative descriptions of psychedelic experiences...

DOI: 10.1080/00952990.2021.1910830 (opens in new tab) Cannabis Narrative Harm reduction Clinical psychology +1

Cannabis effects on brain structure, function, and cognition: considerations for medical uses of cannabis and its derivatives

The American Journal of Drug and Alcohol Abuse July 31, 2019 A. Burggren, Anaheed Shirazi, N. Ginder et al.

ABSTRACT Background: Cannabis is the most widely used illicit substance worldwide, and legalization for recreational and medical purposes has substantially increased its availability and use in the United States.Objectives: Decades of research have suggested that recreational cannabis use confers risk for cognitive impairment across various domains, and structural and functional differences in...

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety.

The American Journal of Drug and Alcohol Abuse 2019 Alan K. Davis, Sara So, Rafael Lancelotta et al. 141 citations

A recent epidemiological study suggested that 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used for spiritual and recreational reasons is associated with subjective improvement in depression and anxiety. Further exploration of the potential psychotherapeutic effects of 5-MeO-DMT could inform future clinical trials. We examined self-reported improvement in depression and anxiety among people who...

Difficulties with emotion regulation, mindfulness, and substance use disorder severity: the mediating role of self-regulation of attention and acceptance attitudes.

The American Journal of Drug and Alcohol Abuse September 14, 2018 Marco Cavicchioli, Mariagrazia Movalli, Cesare Maffei

Background: Theoretical frameworks postulate that mindfulness represents a relevant therapeutic process in substance use disorders (SUDs), especially in treating difficulties with emotion regulation (DER). Nonetheless, it remains unclear how mindfulness dimensions, particularly self-regulation of attention and acceptance attitudes, are implicated in the well-validated relationship between DER...

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.

The American Journal of Drug and Alcohol Abuse 2018 Thomas Kingsley Brown, Kenneth Alper 156 citations

Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel. There are no published prospective studies of drug use outcomes with ibogaine. To study outcomes following opioid detoxification with ibogaine. In this observational study, 30 subjects with DSM-IV Opioid Dependence (25 males, 5...

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.

The American Journal of Drug and Alcohol Abuse 2018 Geoffrey E Noller, Chris M Frampton, Berra Yazar-Klosinski 150 citations

The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. To examine longitudinal treatment effects over a 12-month period among individuals receiving legal ibogaine treatment for opioid dependence. This...

DOI: 10.1080/00952990.2017.1310218 (opens in new tab) Full text (opens in new tab) Legal availability Opioid dependence Opioid detoxification Psychedelics +4

Leveraging user perspectives for insight into cannabis concentrates.

The American Journal of Drug and Alcohol Abuse 2018 Patricia A. Cavazos-Rehg, Melissa J Krauss, Shaina J Sowles et al.

The US has seen an increase in the popularity of highly concentrated forms of cannabis (hereafter concentrates) and too little is known about the potential risks associated with their use. The present study aims to better understand the patterns and outcomes of concentrates use through the perspectives of young adult users. Participants (N = 234, 27.9% female) aged 18-35 years were recruited...

The association of cannabis use on inpatient psychiatric hospital outcomes.

The American Journal of Drug and Alcohol Abuse 2018 Melanie Rylander, Helena R Winston, Haley Medlin et al.

The associations between cannabis use and psychosis are well documented in numerous studies. There is a need to evaluate the impact of cannabis use on inpatient psychiatric utilization and outcomes. To evaluate the impact of cannabis use on psychiatric hospital outcomes. This study was conducted between April 20, 2015 and October 20, 2015. All patients (n = 120) admitted to Denver Health with...

Self-reported use of novel psychoactive substances among attendees of electronic dance music venues.

The American Journal of Drug and Alcohol Abuse November 1, 2016 Joseph J Palamar, Patricia Acosta, Scott J Sherman et al. 73 citations

Novel psychoactive substances (NPSs) continue to emerge in the United States and worldwide. Few epidemiological studies have examined the prevalence and correlates of use. We examined the extent of NPS use in a high-risk population-attendees of electronic dance music (EDM) parties at nightclubs and festivals. We surveyed 682 adults (age 18-25) entering EDM events at nightclubs and festivals in...

DOI: 10.1080/00952990.2016.1181179 (opens in new tab) Full text (opens in new tab) Novel psychoactive substances Synthetic cannabinoids Synthetic cathinones Young adults +13

It’s time to take psilocybin seriously as a possible treatment for substance use disorders

The American Journal of Drug and Alcohol Abuse August 24, 2016 Michael P. Bogenschutz 18 citations

In the current issue of the American Journal of Drug and Alcohol Abuse, Johnson et al. (1) provide long-term outcome data from a smoking cessation pilot study of a treatment model using 2–3 doses o...

DOI: 10.1080/00952990.2016.1200060 (opens in new tab) Psilocybin Substance use Substance abuse treatment Hallucinogen

Long-term follow-up of psilocybin-facilitated smoking cessation

The American Journal of Drug and Alcohol Abuse July 21, 2016 Matthew W. Johnson, Albert Garcia‐romeu, Roland R. Griffiths 702 citations

BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To...

DOI: 10.3109/00952990.2016.1170135 (opens in new tab) Psilocybin Hallucinogen Smoking cessation Term time

Characteristics of novel psychoactive substance exposures reported to New York City Poison Center, 2011-2014.

The American Journal of Drug and Alcohol Abuse December 17, 2015 Joseph J Palamar, Mark K Su, Robert S Hoffman

Background: Novel psychoactive substances (NPS) are emerging at an unprecedented rate. Likewise, prevalence of use and poisonings has increased in recent years. Objective: To compare characteristics of NPS exposures and non-NPS-drug-related exposures and to examine whether there are differences between exposures involving synthetic cannabinoid receptor agonists (SCRAs) and other NPS. Methods:...

Altered resting-state connectivity in adolescent cannabis users.

The American Journal of Drug and Alcohol Abuse November 2013 Catherine Orr, Rowen Morioka, Brendan Behan et al.

Cannabis is the most commonly used illicit drug in adolescence. Heavy use is associated with deficits on a broad range of cognitive functions and heavy use during adolescence may impact development of gray and white matter. To examine differences in intrinsic brain activity and connectivity associated with cannabis dependence in adolescence using whole-brain voxelwise approaches. Adolescents...

A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment

The American Journal of Drug and Alcohol Abuse August 22, 2013 Brittany Vasae Burdick, Bryon Adinoff

Current treatments for addiction are frequently ineffective. Hallucinogenic therapy has been indicated as helpful for a range of substance use disorders, yet this approach remains understudied and publicly unavailable. It is nonetheless a promising treatment, which has significant, long-term beneficial effects with single doses and a profile characterized by general safety, low toxicity, and...

Use of Salvia divinorum in a nationally representative sample.

The American Journal of Drug and Alcohol Abuse 2012 Brian E Perron, Brian K Ahmedani, Michael G. Vaughn et al. 36 citations

Salvia divinorum has known hallucinogenic effects and is legal in most parts of the United States. Given that this psychoactive substance has a potential of misuse and abuse, further data regarding the clinical and psychosocial factors associated with use are needed. To examine the clinical and psychosocial characteristics associated with use of salvia. The study uses data from the National...

CB1 - cannabinoid receptor antagonist effects on cortisol in cannabis-dependent men.

The American Journal of Drug and Alcohol Abuse January 2012 Robert S. Goodwin, Michael H Baumann, David A. Gorelick et al.

The endocannabinoid system modulates the hypothalamic-pituitary-adrenal (HPA) axis, but the effect of cannabinoid type 1 (CB1) receptor antagonism following chronic CB1 receptor stimulation in humans is unknown. To evaluate effects of the CB1 receptor antagonist rimonabant on the HPA axis in cannabis-dependent individuals. Fourteen daily cannabis smokers received increasingly frequent 20 mg...